iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
The antibiotic gap is not just a shortage of promising discoveries. It is the distance between scientific need and a treatment that is developed for the right bacteria, registered in the countries that need it, reliably supplied, and used responsibly. The World Health Organization (WHO) identifies a critical research-and-development gap for antibacterials targeting gram-negative bacteria resistant to carbapenems, while policy sources describe financial and access barriers that can persist even after a drug is developed.
What does “the antibiotic gap” mean?
Antibiotics treat bacterial infections. Antimicrobial resistance (AMR) occurs when microorganisms, including bacteria, become resistant to medicines used against them. For bacterial infections, resistance can make existing antibiotics less effective or ineffective.
The gap is the mismatch between that medical need and the treatments available to meet it. It has several linked parts: candidate medicines may not address the pathogens that pose the greatest concern; promising candidates may not advance through development; approved drugs may not be registered or reliably supplied in every country; and availability must be balanced with appropriate use.
Where is the scientific gap greatest?
WHO identifies a critical research-and-development gap for antibacterials targeting gram-negative bacteria resistant to carbapenems. Gram-negative bacteria are a broad group of bacteria; carbapenems are a class of antibiotics. Resistance to these drugs makes the need for effective alternatives particularly pressing.
#1 Best Overall
WHO says it reviews preclinical and clinical antibacterial development against its priority pathogens list annually. That framing matters: a candidate’s existence in a pipeline does not by itself show that it addresses a high-priority pathogen, is likely to work, or will become an available treatment. In a National Academies chapter discussing the 2023 WHO pipeline review, the assessment is quoted as finding “a glaring insufficiency in novel approaches in the R&D pipeline to effectively combat the increasing emergence and spread of antimicrobial resistance.” The chapter attributes that assessment to the WHO review and the Global AMR R&D Hub, not to an individual speaker.
Why can’t scientific need alone drive antibiotic development?
Antibiotic development is shaped by commercial incentives as well as medical need. Health Canada’s record of a meeting on antimicrobial resistance describes market failure and discussion of “push” and “pull” incentives. Push support helps fund work as it is carried out; pull incentives are designed to reward or support successful development or availability. The meeting record describes the policy discussion, not the current status of any particular incentive program.
Rank #2
Early-stage funding is one part of the response. The OECD identifies CARB-X as a funder of early development for antibiotics, diagnostics, and related products. Supporting early development can help candidates progress, but it does not guarantee that they will succeed in later development, receive authorization, or reach patients.
Why can a developed antibiotic still be hard to obtain?
Discovery and clinical development are only part of the route to access. A medicine also needs regulatory registration in individual markets and a dependable supply chain. Health Canada’s meeting record describes concerns that some new antibiotics may be registered in few countries, as well as shortages and supply interruptions that can disrupt access.
Access is not limited to new drugs. The OECD reports that some older antibiotics with continuing clinical value are not widely available because they were never introduced in some markets or were later withdrawn. That means a gap can persist even when a useful medicine already exists: it may not be obtainable where it is needed.
How do the proposed responses fit together?
Each intervention addresses a different bottleneck. A stronger scientific match does not solve supply problems; funding a candidate does not ensure registration; and wider availability does not replace responsible prescribing and use.
| Gap to address | What the evidence describes | What the response needs to accomplish |
|---|---|---|
| Scientific fit | WHO identifies a critical R&D gap for antibacterials targeting gram-negative carbapenem-resistant bacteria. | Support development directed at high-priority pathogens, rather than treating the number of pipeline candidates as proof that the most important needs are covered. |
| Development and financing | Health Canada’s meeting record discusses antimicrobial market failure and push and pull incentives; the OECD identifies CARB-X as an early-development funder. | Enable promising work to advance while recognizing that early funding alone cannot ensure a successful, authorized medicine. |
| Registration and supply | Health Canada’s meeting record describes limited country registrations, shortages, and supply-chain interruptions; the OECD notes that some useful older antibiotics are not widely available. | Make medicines obtainable in the markets where they are needed and reduce disruptions to dependable supply. |
| Appropriate use | The OECD treats stewardship as part of the policy response to antimicrobial resistance. | Pair access with responsible use so that treatment is available when clinically needed without assuming that unrestricted use is the answer. |
What did the 2008 article with this title report?
John Bonner’s Chemistry World article “Filling the antibiotic gap,” published on 19 September 2008, had the subtitle “Two new targets offer new lines of attack in the battle against drug-resistant strains of bacteria.” The available article record does not identify those targets, so their names cannot be established from that record. Nor should a 2008 report about two targets be read as evidence of the present-day pipeline: the current gap is assessed against today’s research priorities, development progress, and access conditions.
Free tools Windows power users keep installed
One-click scans. No signup required.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
